This week, the CSL Ltd (ASX: CSL) share price hit a 52-week low. Should investors view the ASX healthcare share as a buy?

Csl Ltd ( ($CSLLY) ) has released its Q2 earnings. Here is a breakdown of the information Csl Ltd presented to its investors.

There were positives and negatives in the company's first half performance. The post CSL shares push higher despite 'mixed ...

The CSL Ltd (ASX: CSL) share price will be watched closely today after the biotech giant released its half year ...

In a report released on February 11, Craig Wong-Pan from RBC Capital maintained a Hold rating on CSL (CMXHF – Research Report), with a price ...

The European Commission (EC) has approved Andembry (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and ...

CSL delivered a messy result. Although they did say they are on track to achieve FY guidance, gross margins and 1H adjusted ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

In a report released today, Steven Wheen from Jarden maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$314.37.

Australian biopharmaceutical company CSL posted higher first-half profits as growth in its main blood-plasma business helped offset weaker flu vaccine sales, which were hit by "significantly" low ...